Powered by Business Wire
Search Results for Topix.net

Nordic Nanovector AS: Change in the Board

OSLO, Norway--(BUSINESS WIRE)--

“states Chairman Roy H. Larsen on behalf of the Board.”

Nordic Nanovector informs that Vidar Hansson has decided to step down from the Board of Directors of Nordic Nanovector. ”We are grateful for and would like to thank Vidar for his valuable commitment and contributions since the start of the company. His participation and support have been instrumental in bringing the company to where it is today." states Chairman Roy H. Larsen on behalf of the Board.

About Nordic Nanovector AS

Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

About Betalutin

Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).

This information was brought to you by Cision http://news.cision.com

Contacts

Nordic Nanovector AS
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
or
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no